Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Consensus Rating of “Moderate Buy” by Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $42.75.

A number of equities analysts have weighed in on ASMB shares. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Guggenheim reissued a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Monday, April 20th.

Assembly Biosciences Stock Performance

Shares of Assembly Biosciences stock opened at $27.66 on Monday. The firm’s 50-day simple moving average is $28.56 and its 200-day simple moving average is $30.35. Assembly Biosciences has a twelve month low of $13.81 and a twelve month high of $39.71. The firm has a market cap of $439.52 million, a P/E ratio of -251.43 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. The business had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. On average, equities analysts forecast that Assembly Biosciences will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its stake in Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $147,000. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $228,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $251,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.